Tridek-One
Biotech startup specialising in the research and development of CD31 agonists to restore immune balance
Tridek-One has raised €16M across 1 funding round from 5 investors, most recently a round in Sep 2022. Based in Paris, France; active in Healthtech. Data as of 28 Oct 2026.
Paris, Francetridekone.com ↗
Total raised
€16M
€16,112,890
Funding rounds
1
Investors
5
distinct backers
Active since
2022-09
latest 2022-09
Funding by year
EUR raised per yearTridek-One — funding by year — interactive chart.
Data table
| Tridek-One — funding by year | |
|---|---|
| 2022 | €16M |
Signals
High confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-09-15 | Other | €16M | AdBio partners,Advent Life Sciences,Bioqube Ventures,Bpifrance,Swiss VC Pureos Bioventures | View deal → |
Related news
- French biotech Tridek-One gets €16 million booster to restore the immune balance in patientstech.eu · 2022-09
- Tridek-One raises $16.1M to develop first-in-class tech for immune balancetechfundingnews.com · 2022-09
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData